Toggle menu

PitSTOP

Start date:
August 2017
End date:
August 2018
Co-ordinated by:
Dr John Emelifeonwu and the EMERGE Team, RIE
Main trial site:
RIE

Primary Objective
To determine the prevalence of anterior pituitary gland dysfunction in traumatic brain injury in Scotland.

Secondary Objectives
To determine whether clinical and radiologically parameters available on presentation can predict likelihood of developing PTPD in patients with TBI.
To determine the optimal timing after TBI for blood tests to diagnose PTPD
To determine whether PTPD effects functional recovery as determined by the extended Glasgow Outcome Score (eGOS)

Chief Investigator

Dr John Emelifeonwu

Surgical Trainee, Clinical Neurosciences

Research Team

Mia Paderanga

Senior Research Nurse

Julia Grahamslaw

Lead Research Nurse

More EMERGE Trials

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Read more

ATTEST2

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Traumatic Brain Injury (TBI) is the leading cause of death and disabilities amongst young people worldwide. Many sufferers develop chronic physical and mental health problems and are unable to work or re-engage socially after their injuries. There are therefore significant health and socioeconomic consequences.

Read more

PitSTOP

A study examining the Prevalence and Risk of Anterior Pituitary Dysfunction following Traumatic Brain Injury

Global Anticoagulant Registry in the FIELD observing treatment and outcomes in patients with treated acute Venous Thromboembolic Events in the real world

Read more

Garfield-VTE

Global Anticoagulant Registry In the FIELD – Venous Thromboembolic Events